SCHEMBL24216698

SCHEMBL24216698

CC(C)(N)C(=O)Nc1cccc(-c2cn(Cc3ccc(-c4nnc(C(F)F)o4)cn3)nn2)c1

nearest known ligand 0.49

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ HDAC6 Q9UBN7 14/20 0.49
▸ KDM4E B2RXH2 1/20 0.42
▸ KDR P35968 2/20 0.41
▸ TEK Q02763 1/20 0.41
▸ UCHL5 Q9Y5K5 1/20 0.40
▸ HDAC1 Q13547 4/20 0.39
▸ HDAC3 O15379 3/20 0.39
▸ HDAC2 Q92769 2/20 0.39
▸ HDAC10 Q969S8 2/20 0.39
▸ HDAC8 Q9BY41 2/20 0.39
▸ SIRT2 Q8IXJ6 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30409392 1.00 HDAC6 (0.49) HDAC6KDM4EKDRTEKUCHL5
SCHEMBL25350996 0.94 HDAC6 (0.49) HDAC6KDM4EKDRTEKUCHL5
SCHEMBL30410398 0.94 HDAC6 (0.49) HDAC6KDM4EKDRTEKUCHL5
SCHEMBL30408530 0.94 HDAC6 (0.49) HDAC6KDM4EKDRTEKUCHL5
SCHEMBL24216211 0.94 HDAC6 (0.49) HDAC6KDM4EKDRTEKUCHL5
SCHEMBL25350716 0.92 HDAC6 (0.47) HDAC6KDM4EKDRTEKUCHL5
SCHEMBL30410460 0.91 HDAC6 (0.47) HDAC6KDM4EKDRTEKUCHL5
SCHEMBL25352280 0.91 HDAC6 (0.46) HDAC6KDM4EKDRTEKUCHL5
SCHEMBL25216547 0.90 HDAC6 (0.51) HDAC6KDRTEKUCHL5HDAC1
SCHEMBL30424695 0.90 HDAC6 (0.51) HDAC6KDRTEKUCHL5HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230257372-A1 NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2023-08-17 — — US disclosed
US-20230257372-A1 NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2023-08-17 — — US disclosed
US-20230257372-A1 NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2023-08-17 — — US disclosed
WO-2022013728-A1 NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2022-01-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230257372-A1 NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME HDAC6, HDAC1, HDAC3 HDAC6 1/4885KDM4E 544/4885KDR 4706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback